Andrew Dudum, Hims & Hers CEO
April 29, 2025 07:30 AM EDTUpdated 09:26 AM
Pharma
Health Tech

Hims and No­vo Nordisk part­ner to of­fer dis­count­ed We­govy

Shelby Livingston

Health tech correspondent

In an un­like­ly part­ner­ship be­tween two ri­vals, Hims & Hers said its mem­bers will now be able to get No­vo Nordisk’s weight loss drug We­govy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA de­lays PDU­FA date for small biotech, rais­ing ques­tions about im­pact of agency cuts

Pfiz­er launch­es a new wave of cost cuts, ex­pects $7.7B in to­tal sav­ings through 2027

FDA ap­proves Abeona’s skin dis­ease cell ther­a­py

As­traZeneca, No­var­tis ex­e­cute ‘US for US’ strat­e­gy as phar­ma tar­iffs near

Oc­ta­gon Ther­a­peu­tics shuts down af­ter 'un­re­solved bi­ol­o­gy ques­tion­s'

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times